Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up

• Príomhchruthaitheoirí: Antonio Lacquaniti (Údar), Patrizio Pasqualetti (Údar), Teresa Casuscelli di Tocco (Údar), Susanna Campo (Údar), Stefania Rovito (Údar), Maurizio Bucca (Údar), Antonino Ragusa (Údar), Paolo Monardo (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: The Korean Society of Nephrology, 2020-09-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Background : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have...